BJ-005 / BJ Biosci - LARVOL DELTA

A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma (clinicaltrials.gov) - P1 | N=85 | Active, not recruiting | Sponsor: BJ Bioscience, Inc. | Recruiting ➔ Active, not recruiting | Trial primary completion date: Oct 2023 ➔ Oct 2024

Enrollment closed • Metastases • Trial primary completion date • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor